← Back to Screener
Ionis Pharmaceuticals, Inc. Common Stock (IONS)
Price$74.48
Value ScoreF
Growth ScoreB
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-17.90%
Price vs S&P 500 (4W)-1.62%
VGM Score50.90
Market Capitalization$12.31B
All Metrics
Book Value / Share (Quarterly)$2.96
P/TBV (Annual)5.79x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)17.12%
Cash Flow / Share (Quarterly)$-5.85
Price vs S&P 500 (YTD)-14.01%
Gross Margin (TTM)98.35%
Net Profit Margin (TTM)-30.90%
EPS (TTM)$-2.10
10-Day Avg Trading Volume1.56M
EPS Excl Extra (TTM)$-2.10
Revenue Growth (5Y)5.29%
EPS (Annual)$-2.38
ROI (Annual)-13.53%
Gross Margin (Annual)98.31%
Net Profit Margin (5Y Avg)-40.14%
Cash / Share (Quarterly)$11.57
Revenue Growth QoQ (YoY)86.43%
ROA (Last FY)-10.82%
Revenue Growth TTM (YoY)47.38%
EBITD / Share (TTM)$-2.04
ROE (5Y Avg)-60.13%
Operating Margin (TTM)-33.29%
Cash Flow / Share (Annual)$-1.96
P/B Ratio25.05x
P/B Ratio (Quarterly)25.35x
Net Income / Employee (Annual)$-272,000
EV / Revenue (TTM)13.68x
Net Interest Coverage (TTM)-4.22x
ROA (TTM)-10.07%
EV / EBITDA (TTM)432.09x
EPS Incl Extra (Annual)$-2.38
Current Ratio (Annual)3.83x
Quick Ratio (Quarterly)4.09x
3-Month Avg Trading Volume2.00M
52-Week Price Return111.35%
Revenue / Employee (TTM)$754,800
Tangible BV / Share (Quarterly)$3.98
P/S Ratio (Annual)13.04x
Asset Turnover (Annual)0.27x
52-Week High$86.74
Operating Margin (5Y Avg)-45.13%
EPS Excl Extra (Annual)$-2.38
CapEx CAGR (5Y)7.95%
Tangible BV CAGR (5Y)56.47%
26-Week Price Return-9.97%
Quick Ratio (Annual)3.81x
13-Week Price Return-0.90%
Total Debt / Equity (Annual)4.77x
Current Ratio (Quarterly)4.10x
Enterprise Value$14.47B
Revenue / Share Growth (5Y)2.46%
Asset Turnover (TTM)0.33x
Book Value / Share Growth (5Y)-10.77%
Revenue / Employee (Annual)$673,100
Inventory Turnover (Annual)1.41x
Pretax Margin (Annual)-40.22%
Cash / Share (Annual)$16.40
3-Month Return Std Dev27.96%
Gross Margin (5Y Avg)98.36%
Net Income / Employee (TTM)$-233,200
ROE (Last FY)-77.98%
Net Interest Coverage (Annual)-13.03x
EPS Basic Excl Extra (Annual)$-2.38
P/FCF (TTM)88.53x
Receivables Turnover (TTM)18.66x
Total Debt / Equity (Quarterly)4.76x
EPS Incl Extra (TTM)$-2.10
Receivables Turnover (Annual)11.93x
ROI (TTM)-12.49%
P/S Ratio (TTM)11.63x
Pretax Margin (5Y Avg)-39.07%
Revenue / Share (Annual)$5.90
Tangible BV / Share (Annual)$5.26
Price vs S&P 500 (52W)86.99%
Year-to-Date Return-5.85%
5-Day Price Return-1.19%
EPS Normalized (Annual)$-2.38
ROA (5Y Avg)-9.98%
Net Profit Margin (Annual)-40.41%
Month-to-Date Return-2.64%
Cash Flow / Share (TTM)$-2.77
EBITD / Share (Annual)$-2.32
Operating Margin (Annual)-40.45%
LT Debt / Equity (Annual)3.88x
ROI (5Y Avg)-13.25%
LT Debt / Equity (Quarterly)3.88x
EPS Basic Excl Extra (TTM)$-2.10
P/TBV (Quarterly)11.12x
P/B Ratio (Annual)26.20x
Inventory Turnover (TTM)2.04x
Pretax Margin (TTM)-30.72%
Book Value / Share (Annual)$2.99
Price vs S&P 500 (13W)-9.16%
Beta0.38x
P/FCF (Annual)654.72x
Revenue / Share (TTM)$6.42
ROE (TTM)-58.65%
52-Week Low$34.78
vGradeF
gGradeB
mGradeB
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.56est. -0.93
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.07
4.07
4.10
4.12
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
IONSIonis Pharmaceuticals, Inc. Common Stock | F | B | B | $74.48 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Ionis Pharmaceuticals is a leader in antisense technology with a diverse clinical pipeline targeting cardiovascular, metabolic, neurological, and rare diseases. The company has established multiple marketed drugs through partnerships, including Spinraza (spinal muscular atrophy), Qalsody (ALS), and Tegsedi (ATTR amyloidosis), while achieving its first independent launches in 2025 with Tryngolza and Dawnzera. Ionis combines partnership-driven revenue streams with growing direct commercialization capabilities.